Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

What happened

Faeth Therapeutics appointed Adam Schayowitz, Ph.D., MBA, to its Board of Directors. He is Executive Vice President and Head of Research and Development at Zymeworks and has nearly 20 years of oncology drug development experience.

Confirmed

Global impact / market context

Schayowitz has led global development programs that reached regulatory approval, including Zejula work at Tesaro. His board perspective could help Faeth advance PIKTOR, its lead program, through Phase 1b/2 trials in endometrial and breast cancer.

Analyst inference

Faeth is a clinical-stage oncology company, meaning its therapies are still in human testing and may not reach the market. Adding a director with approval and commercialization experience can support investor confidence without changing near-term cash needs.

Analyst inference

What to watch

1. Faeth is evaluating PIKTOR in a Phase 1b/2 trial, which tests safety and early effectiveness in patients. The company said it is studying the program in endometrial and breast cancer. Confirmed
2. Watch whether Faeth discloses further PIKTOR trial progress, since the article names no timeline, enrollment figures, or results. Such updates would show whether the board appointment accompanies clinical momentum. Proposed
3. For Zymeworks investors, Schayowitz's added board role may raise questions about demands on his time. Any later Zymeworks research leadership change or pipeline delay could draw scrutiny. Analyst inference

Evidence

• Original source link unavailable